Table 2 Clinicopathologic features of seven patients with neuroendocrine carcinoma of the breast
From: Neuroendocrine carcinoma of the breast: a review of 126 cases in China
No. | Age (years) | Sex | Symptom | Histology | TNM stage | Intrinsic subtype | Treatment | Follow-up outcome |
|---|---|---|---|---|---|---|---|---|
1 | 49 | F | Breast lump | Well-differentiated | T2N0M0, IIA | ER3+PR2+HER2− | Surgery, chemotherapy, and endocrine therapy | Alive without tumor |
2 | 78 | F | Breast lump | Well-differentiated | T1N0M0, IA | ER3+PR3+HER2− | Surgery, chemotherapy, and endocrine therapy | Died of other causes |
3 | 49 | F | Breast lump | Poorly-differentiated | T2N0M0, IIA | ER3+PR+HER2− | Surgery, chemotherapy, and endocrine therapy | Alive without tumor |
4 | 58 | F | Breast lump | Well-differentiated | T2N1M0, IIB | ER2+PR2+HER2− | Surgery, chemotherapy, and endocrine therapy | Alive without tumor |
5 | 43 | F | Breast lump and skin ulceration | Well-differentiated | T3N2M0, IIIA | ER−PR−HER2− | Surgery and chemotherapy | Alive without tumor |
6 | 60 | M | Breast lump | Poorly-differentiated | T4N0M1, IV | ER−PR−HER2− | Chemotherapy | Lost to follow-up |
7 | 33 | F | Breast lump | Well-differentiated | T2N1M0, IIB | ER3+PR2+HER2− | Surgery, chemotherapy, and endocrine therapy | Alive without tumor |